PubRank

Incretin effect and glucagon responses to oral and intravenous glucose in patients with maturity-onset diabetes of the young--type 2 and type 3.

PubWeight™: 1.43‹?› | Rank: Top 5%

🔗 View Article (PMID 24677712)

Published in Diabetes on March 27, 2014

Authors

Signe H Østoft1, Jonatan I Bagger2, Torben Hansen3, Oluf Pedersen4, Jens J Holst5, Filip K Knop2, Tina Vilsbøll6

Author Affiliations

1: Diabetes Research Division, Department of Medicine, Gentofte Hospital, University of Copenhagen, Copenhagen, DenmarkDepartment of Biomedical Sciences, Panum Institute, University of Copenhagen, Copenhagen, DenmarkNovo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, Copenhagen, Denmark s.ostoft@dadlnet.dk.
2: Diabetes Research Division, Department of Medicine, Gentofte Hospital, University of Copenhagen, Copenhagen, DenmarkDepartment of Biomedical Sciences, Panum Institute, University of Copenhagen, Copenhagen, DenmarkNovo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, Copenhagen, Denmark.
3: Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, Copenhagen, DenmarkFaculty of Health Sciences, University of Southern Denmark, Odense, Denmark.
4: Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, Copenhagen, Denmark.
5: Department of Biomedical Sciences, Panum Institute, University of Copenhagen, Copenhagen, DenmarkNovo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, Copenhagen, Denmark.
6: Diabetes Research Division, Department of Medicine, Gentofte Hospital, University of Copenhagen, Copenhagen, Denmark.

Articles citing this ↘

Incretin physiology and pathophysiology from an Asian perspective. J Diabetes Investig (2014) 0.91

Basal insulin combined incretin mimetic therapy with glucagon-like protein 1 receptor agonists as an upcoming option in the treatment of type 2 diabetes: a practical guide to decision making. Ther Adv Endocrinol Metab (2014) 0.77

A computer model simulating human glucose absorption and metabolism in health and metabolic disease states. F1000Res (2016) 0.75

Diabetes. Attenuated incretin effect after glucose loading in monogenic HNF1A diabetes. Nat Rev Endocrinol (2014) 0.75

Heterozygous RFX6 protein truncating variants are associated with MODY with reduced penetrance. Nat Commun (2017) 0.75

Articles by these authors ⇆

Insulin Resistance Is Accompanied by Increased Fasting Glucagon and Delayed Glucagon Suppression in Individuals With Normal and Impaired Glucose Regulation. Diabetes (2016) 0.82

Metabolomic and microbiome profiling reveals personalized risk factors for coronary artery disease. Nat Med (2022) 0.75